Molecule intelOpportunity: Lower0Crowded market

Pregabalin

137 brands · 82 companies · product forms

2 DRAP alerts

Opportunity snapshot

Launch attractiveness
25
Market saturation
97
Price room
100
Regulatory risk
70
137
brands
82
companies
Rs 331.1
median price
157
price points
100.81x
price spread
90
confidence %

Who competes here

Top companies by brand count — fragmented market (no dominant player) · leader share 3%

Price room

Across observed sources and strengths
CheapestRs 29.93
MedianRs 331.1
Most expensiveRs 3,017.13
Spread100.81×
Sources: DRAP-official, DVAGO, Servaid

max/min price ratio 100.81x across 157 trusted points (Rs 29.93-3017.13). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Brands & products on the market

Sample of 12 live products for Pregabalin — each links to its own medicine page.

Regulatory alerts

Safety exposurelatest 2026-03-11
Rapid Alert: Drug Product; Falsified Tablin 300mg Capsule identified in the market
12. Rapid Alert – SPURIOUS CAPSULE GABICA 300 mg (BATCH NO. 518C27)

Why this score

Launch attractiveness

40% supply-gap(0) + 25% price-variation(100) + 20% low-competition(3) + 15% supply-disruption(0), damped by confidence(90). Higher = more attractive, less crowded opportunity.

Market saturation

82 canonical companies and 137 brands compete (saturation pegged at 30 companies / 150 brands).

Price room

max/min price ratio 100.81x across 157 trusted points (Rs 29.93-3017.13). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Regulatory risk

2 DRAP alert(s), latest 2026-03-11 incl. recall/safety.

Confidence

Reduced by: no ATC code.

Packaged brief for this lower opportunity?

Molecule page + company profiles + price-room analysis are the pilot package for pharma teams.

See packaged reports All 3868 molecules

Molecule intelligence as of 2026-07-30. Brand/company counts from DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.